Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064839 | 0.86 | CNR1 (0.72) | CNR1ALDH1A1RECQLSIRT5PLEC | |
| SCHEMBL5057174 | 0.78 | ALDH1A1 (0.55) | CNR1ALDH1A1RECQLSIRT5PLEC | |
| SCHEMBL14206275 | 0.78 | CNR1 (0.52) | CNR1TP53LMNAPOLBSMN1; SMN2 | |
| SCHEMBL5576876 | 0.78 | CNR1 (0.64) | CNR1ALDH1A1TP53LMNAPOLB | |
| SCHEMBL5057655 | 0.78 | DRD2 (0.54) | CNR1ALDH1A1RECQLSIRT5PLEC | |
| SCHEMBL5062827 | 0.76 | CNR1 (0.66) | CNR1ALDH1A1TP53LMNAPOLB | |
| SCHEMBL5064758 | 0.74 | PLEC (0.55) | CNR1ALDH1A1RECQLSIRT5PLEC | |
| SCHEMBL14542214 | 0.73 | CNR1 (0.75) | CNR1PLECTP53LMNAPOLB | |
| SCHEMBL5058777 | 0.73 | CNR1 (0.75) | CNR1ALDH1A1TP53LMNAPOLB | |
| SCHEMBL5062757 | 0.72 | CNR1 (0.70) | CNR1ALDH1A1TP53LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | CNR1 1/4885ALDH1A1 888/4885RECQL 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.